3-(2-DIMETHYLAMINOMETHYLCY CLOHEXYL)PHENOL RETARD FORMULATION

The invention relates to a dosage form for controlled release of the active ingredient 3-(2-dimethylaminomethylcyclohexyl)phenol, preferably (1R,2R)-3-(2-dimethylamino-methylcyclohexyl)phenol, or one of the pharmaceutically acceptable salts thereof, which (i) in vivo achieves the peak plasma level o...

Full description

Saved in:
Bibliographic Details
Main Authors BARTHOLOMAUS JOHANNES, JUNG TOBIAS
Format Patent
LanguageEnglish
Published 23.04.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to a dosage form for controlled release of the active ingredient 3-(2-dimethylaminomethylcyclohexyl)phenol, preferably (1R,2R)-3-(2-dimethylamino-methylcyclohexyl)phenol, or one of the pharmaceutically acceptable salts thereof, which (i) in vivo achieves the peak plasma level of the active ingredient after 2 to 10 h, and/or (ii) in vitro, measured in accordance with the European Pharmacopoeia with a paddle stirrer apparatus in buffer at a pH value of 6.8 (preferably 900 ml), a temperature of 37° C. and 75 rpm releases after 0.5 hours 3.0 to 37 wt. %, after 1 hour 5.0 to 56 wt. %, after 2 hours 10 to 77 wt. %, after 3 hours 15 to 88 wt. %, after 6 hours at least 30 wt. %, after 12 hours at least 50 wt. %, after 18 hours at least 70 wt. % and after 24 hours at least 80 wt. % of the active ingredient originally contained in the dosage form.
Bibliography:Application Number: US20060066927